Abstract
Aims Early prediction of acute coronary syndrome (ACS) is a major goal for prevention of coronary heart disease (CHD). Genetic information has been proposed to improve prediction beyond well-established clinical risk factors. While polygenic scores (PS) can capture an individual’s genetic risk for ACS, its prediction performance may vary in the context of diverse correlated clinical conditions. Here, we aimed to test whether clinical conditions impact the association between PS and ACS.
Methods and Results We explored the association between 405 clinical conditions diagnosed before baseline and 9,080 incident cases of ACS in 387,832 individuals from the UK Biobank. We identified 80 conventional (e.g., stable angina pectoris (SAP), type 2 diabetes mellitus) and unconventional (e.g., diaphragmatic hernia, inguinal hernia) associations with ACS. Results were replicated in 6,430 incident cases of ACS in 177,876 individuals from FinnGen. The association between PS and ACS was consistent in individuals with and without most clinical conditions. However, a diagnosis of SAP yielded a differential association between PS and ACS. PS was associated with a significantly reduced (interaction p-value=2.87×10−8) risk for ACS in individuals with SAP (HR=1.163 [95% CI: 1.082–1.251]) compared to individuals without SAP (HR=1.531 [95% CI: 1.497–1.565]). These findings were replicated in FinnGen (interaction p-value=1.38×10−6).
Conclusion In summary, while most clinical conditions did not impact utility of PS for prediction of ACS, we found that PS was substantially less predictive of ACS in individuals with prevalent stable CHD. PS for ACS may be more appropriate for asymptomatic individuals than symptomatic individuals with clinical suspicion for CHD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Stanford University Undergraduate Research Student Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank was approved by the National Health Service National Research Ethics Service and all participants provided written informed consent. FinnGen was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data are available by request at https://www.ukbiobank.ac.uk/using-the-resource/. FinnGen data are available by request at https://www.finngen.fi/en/access_results.
